US Myeloma Innovations Research Collaborative (USMIRC)
Research facility
Location:
Kansas City,
United States (USA) (US)
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy (2024)
Merz M, Dima D, Hashmi H, Ahmed N, Stölzel F, Holderried TA, Fenk R, et al.
Journal article
Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma. (2024)
Gagelmann N, Dima D, Merz M, Hashmi H, Ahmed N, Tovar N, Oliver-Caldés A, et al.
Journal article